FDA seeks new warnings on arthritis drugs

The FDA has requested that Pfizer, Eli Lilly, and AbbVie include additional warnings on their arthritis drugs about the risks of serious conditions and death that can occur.

The request follows the FDA’s review of Pfizer’s drug Xeljanz after a February trial found an increased risk of serious heart-related problems and cancer with the treatment.

Pfizer said the update would bring important clarity for healthcare providers on the risk/benefit profile of Xeljanz.

read more